Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/98080
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes
Author: Wouldes, T.
Battin, M.
Coat, S.
Rush, E.
Hague, W.
Rowan, J.
Citation: Archives of Disease in Childhood: Fetal and Neonatal Edition, 2016; 101(6):F488-F493
Publisher: BMJ Publishing Group
Issue Date: 2016
ISSN: 1359-2998
1468-2052
Statement of
Responsibility: 
Trecia A Wouldes, Malcolm Battin, Suzette Coat, Elaine C Rush, William M Hague, Janet A Rowan
Abstract: OBJECTIVE Gestational diabetes mellitus (GDM) is a common complication of pregnancy and is increasingly being treated with metformin that crosses the placenta rather than insulin, which does not. This study seeks to examine the neurodevelopment of offspring of women treated with metformin or insulin for GDM. DESIGN We performed a prospective follow-up study of children whose mothers had been randomly assigned at 20–33 weeks gestation to treatment with metformin or insulin for GDM. Of the 211 children followed up at 2 years, 128 were from Auckland, New Zealand (64 metformin vs 64 insulin), and 83 from Adelaide, Australia (39 metformin vs 49 insulin). Neurodevelopment was examined with the Bayley Scales of Infant Development V.2 mental development index (MDI) and psychomotor development index (PDI). Clinical and demographic background characteristics were obtained at enrolment, birth and follow-up. RESULTS No significant differences were found between treatment groups in clinical or demographic characteristics. The MDI and PDI composite scores were tested with general linear models. No significant differences were found between metformin and insulin, respectively, in New Zealand (MDI, M=83.6 vs 86.9 and PDI, M=83.4 vs M=85.2) or Australia (MDI, M=102.5 vs M=98.4 and PDI, M=105.6 vs M=99.9) and no interactions observed. The differences in neurodevelopmental outcomes between the Auckland and Adelaide cohorts were explained by parental ethnicity, infant birth weight >4000 g, neonatal hypoglycaemia, maternal glycaemia and smoking in the household. CONCLUSIONS This study provides additional data supporting the safety of metformin in the treatment of GDM. TRIAL REGISTRATION NUMBER ACTRN 12605000311651.
Keywords: Gestational Diabetes Mellitus; Metformin; Neurodevelopment; Outcomes research
Rights: Copyright Article author (or their employer) 2016.
RMID: 0030043919
DOI: 10.1136/archdischild-2015-309602
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.